FINANCINGS
Applied Genetic Technologies Corp. sold 2 million shares at $15 each in a public offering.
Avalanche Biotechnologies Inc. raised $102 million from its IPO selling 6 million shares at $17 each.
Bio Blast Pharma Ltd. priced 3.2 million shares at $11 each in its IPO for gross proceeds of $35.2 million.
Celladon Corp. filed a prospectus for a proposed $63.3 million public offering.
Cold Genesys Inc. raised $13.6 million from a series A financing.
Contrafect Corp. priced its IPO for gross proceeds of $36 million to advance its pipeline against drug-resistant pathogens.
Eyegate Pharma Inc. filed for a $30.3 million IPO.
Immune Design Corp. closed its IPO for aggregate gross proceeds of $60 million.
Innocoll AG closed a public offering for estimated net proceeds of about $51.5 million.
La Jolla Pharmaceuticals Inc. closed its public offering of about 5.4 million shares at $10.50 per share.
Macrocure Ltd., in its IPO, priced about 5.4 million shares at $10 apiece raising $53.3 million in gross proceeds.
Marinus Pharmaceuticals Inc., in its IPO, raised $65 million from 5 million shares at $13 each.
Ocular Therapeutix Inc. closed its IPO of 5 million shares at $13 each for net proceeds of about $60.5 million.
Pfenex Inc. closed its IPO of 8.3 million shares at $6 apiece for gross proceeds of about $50 million.
VBL Therapeutics sold 5.4 million shares at $12 each in its IPO.
DEALS
Almirall SA said Astrazeneca plc is acquiring its respiratory disease portfolio of partnered and pipeline assets.
Amorchem LP and Roche AG are collaborating to discover a small-molecule therapy to treat myotonic muscular dystrophy 1.
Artes Biotechnology GmbH and the Burnet Institute are developing a new type of malaria vaccine.
Cellectis AB sold its subsidiary Cellectis AB to Takara Bio Inc. and will focus its activities in oncology.
Endo International plc completed the acquisition of Grupo Farmaceutico Somar.
Kalobios Pharmaceuticals Inc. asked for and received the rights to KB001-A from Sanofi Pasteur.
Meda AB said it plans to acquire Rottapharm Madaus SpA for $3.1 billion.
Paxvax Inc. acquired oral typhoid vaccine Vivotif from Crucell Switzerland AG.
Pfizer Inc. is acquiring Baxter International Inc.'s portfolio of marketed vaccines for $635 million.
Proteostasis Therapeutics Inc. completed a key preclinical milestone in its collaboration with Biogen Idec Inc.
Rogne Bioscience Inc. acquired a license to anti-inflammatory peptides from Isis Innovation, the commercialization arm of the University of Oxford, UK.
Stallergenes SA is acquiring Argentina's Alergo Pharma Srl to boost its presence in Latin America.
Theraclone Sciences Inc. is licensing its broadly neutralizing HIV-antibodies to Gilead Sciences Inc.
Variation Biotechnologies (US) Inc. completed a merger with Paulson Capital (Delaware) Corp. and will become a wholly owned subsidiary of Paulson, which will be known as VBI Vaccines Inc.
Zealand Pharma A/S signed a second drug development deal in diabetes with Boehringer Ingelheim GmbH.
. . . AND MORE
Acelrx Pharmaceuticals Inc. received an FDA complete response letter for Zalviso, a pain management product.
The EMA gave the nod to Accofil from Accord Healthcare Ltd., a biosimilar version of Amgen Inc.'s Neupogen.
The UK government announced a $132 million contract with Illumina Inc. to deliver the equipment and services for its 100,000 Genomes Project.
Targacept Inc.'s TC-5214 in the treatment of overactive bladder failed to show statistical significance in improving urinary incontinence in a phase II trial.
Theravectys SAS filed suit against Immune Design Corp. to prevent it from using lentiviral vector vaccines developed or produced by Theravectys' exclusive manufacturer, Henogen SA.